Background: This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). Patients and methods: Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m2 intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. Results: Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. Conclusion: We conclude that gemcitabine is not an active drug in ACC.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) / C.M.L. van Herpen, L.D. Locati, J. Buter, J. Thomas, J. Bogaerts, D. Lacombe, P. de Mulder, A. Awada, L. Licitra, J. Bernier, J.B. Vermorken. - In: ELSEVIER. - ISSN 0922-3444. - 44:17(2008 Nov), pp. 2542-2545.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)

L. Licitra;
2008

Abstract

Background: This phase II study was conducted to determine the antitumour activity of gemcitabine in adenoid cystic carcinoma (ACC). Patients and methods: Patients with progressive and/or symptomatic, recurrent and/or metastatic ACC were treated with gemcitabine 1250 mg/m2 intravenous (i.v.) on days 1 and 8 of each 21-day cycle. Each cycle was repeated every 3 weeks in the absence of disease progression for a minimum of four cycles and a maximum of 12 cycles. Results: Among 21 ACC patients, there were no objective responses. Eleven patients had a stable disease, of which ten patients for more than 6 months, and eight had a progressive disease after 4 cycles. Gemcitabine was well tolerated by most patients. Conclusion: We conclude that gemcitabine is not an active drug in ACC.
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Phase II study .pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 202.67 kB
Formato Adobe PDF
202.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/577587
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 44
social impact